The Choice between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?

44Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.
Get full text

Abstract

When oral dopaminergic medication falls short in the treatment of Parkinson's disease, patients are left with motor response fluctuations and dyskinesias that may have a large impact on functioning in daily life. They may benefit from one of the currently available advanced treatments, namely deep brain stimulation, continuous levodopa-carbidopa intestinal gel, and continuous subcutaneous apomorphine infusion. The indication, choice between the separate advanced treatments and the timing can be challenging and will be discussed against the background of the progressive nature of the disease, the heterogeneity of disease manifestation and variable patient characteristics.

Cite

CITATION STYLE

APA

Dijk, J. M., Espay, A. J., Katzenschlager, R., & De Bie, R. M. A. (2020). The Choice between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? Journal of Parkinson’s Disease. IOS Press BV. https://doi.org/10.3233/JPD-202104

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free